HIV-1 Vaccine Based on Chimp Serotypes of Adenovirus

基于黑猩猩腺病毒血清型的 HIV-1 疫苗

• 批准号: 7925783
• 负责人: Hildegund C. J. Ertl
• 金额: $ 304.17万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7925783
• 关键词: HIV; Vaccine; Based; Chimp; Serotypes

This program focuses on vaccine candidates for HIV-1 based on two replication-defective chimpanzee (chimp) adenovirus (Ad) vectors, termed AdC6 and AdC7. The program has four interlinked goals. Our first goal is to pursue clinical development of AdC6 and AdC7 vectors expressing gag of HIV-1 to test the safety of each vector in dose-escalation phase I trials, and to assess the immunogenicity of both vectors combined in a heterologous prime boost regimen in a phase IIA trial. Clinical trials will be conducted under the auspices of the NIAID-sponsored HIV Vaccine Trials Network (HVTN). Our second goal is to further optimize the AdC6 and AdC7 vectors for later stage clinical trials. Our third goal is a research objective to define the quality of T cell responses to AdC6/AdC7 prime boost regimens in both experimental animals and human vaccine recipients. Evidence is mounting that different vaccine regimens not only influence the magnitude but also the quality of the ensuing cellular immune responses, and that this quality substantially influences progression of HIV-1 infections toward disease. Vaccine-induced correlates of protection against HIV-1 associated illness remain poorly defined, which has made it difficult to compare the clinical potential of the vectors considered as platforms for a candidate HIV vaccine. We aim to carefully define pertinent characteristics of the cellular immune responses elicited by chimp Ad vector prime boost regimens in preclinical models, and how such characteristics correlate with protection against challenge with model pathogens. Our fourth goal is to elucidate the effect of pre-existing T cells to conserved antigens of Ads on the performance of chimp Ad vectors as vaccine carriers. The prevalence of such T cells will be determined in human cohorts from the US and Africa. Their effect on vaccine-induced T cell responses will first be assessed in experimental animals and then in human vaccine recipients. Definition of the characteristics of effective immune responses in animals with comparison studies in human vaccine recipients will advance our understanding of the correlates of immune protection to be pursued in future efforts of AIDS vaccine development.

该计划的重点是基于两种复制缺陷型黑猩猩腺病毒（Ad）载体（称为AdC 6和AdC 7）的HIV-1候选疫苗。该计划有四个相互关联的目标。我们的第一个目标是进行表达HIV-1 gag的AdC 6和AdC 7载体的临床开发，以测试每种载体在剂量递增I期试验中的安全性，并评估在IIA期试验中在异源初免加强方案中组合的两种载体的免疫原性。临床试验将在NIAID赞助的HIV疫苗试验网络（HVTN）的主持下进行。我们的第二个目标是进一步优化AdC 6和AdC 7载体用于后期临床试验。我们的第三个目标是确定实验动物和人类疫苗接受者对AdC 6/AdC 7初免加强方案的T细胞应答的质量。越来越多的证据表明，不同的疫苗方案不仅影响随后的细胞免疫应答的程度，而且影响其质量，并且这种质量实质上影响HIV-1感染向疾病的进展。疫苗诱导的对HIV-1相关疾病的保护相关性仍然定义不清，这使得难以比较被认为是候选HIV疫苗平台的载体的临床潜力。我们的目标是仔细定义相关的特性引起的黑猩猩Ad载体的初免加强方案在临床前模型中的细胞免疫应答，以及如何保护这些特性与模型病原体的挑战。我们的第四个目标是阐明预先存在的T细胞对作为疫苗载体的黑猩猩Ad载体的性能的影响。这些T细胞的流行率将在美国和非洲的人类队列中确定。它们对疫苗诱导的T细胞反应的影响将首先在实验动物中进行评估，然后在人类疫苗接受者中进行评估。动物有效免疫应答的特征的定义与人类疫苗接受者的比较研究将促进我们对未来艾滋病疫苗开发中所追求的免疫保护相关性的理解。